Phathom Pharmaceuticals stock hits 52-week low at $5.21

Published 03/03/2025, 21:24
Phathom Pharmaceuticals stock hits 52-week low at $5.21

In a challenging year for Phathom Pharmaceuticals Inc., the company’s stock has reached a 52-week low, trading at $5.21, significantly below analyst targets ranging from $17 to $28. According to InvestingPro analysis, the stock appears undervalued at current levels. This price point marks a significant downturn for the pharmaceutical firm, which has seen its shares plummet by 66% over the past six months. While investors remain cautious amid market volatility, the company maintains strong liquidity with a current ratio of 5.73, indicating ample resources to meet short-term obligations. The current low presents a critical moment for Phathom Pharmaceuticals as it looks to regain its footing and reassure shareholders of its long-term potential. Get deeper insights and access 10 additional exclusive InvestingPro Tips to make more informed investment decisions.

In other recent news, Phathom Pharmaceuticals has been actively engaging with the FDA to clarify the exclusivity status of its VOQUEZNA product line. The company filed a Citizen’s Petition to align the exclusivity period for its VOQUEZNA tablets with that of the VOQUEZNA Dual and Triple Pak, which currently enjoy a 10-year exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act. This initiative is aimed at extending VOQUEZNA’s market protection until 2032, thereby preventing generic competition earlier than anticipated. Analysts from Stifel and H.C. Wainwright have maintained a Buy rating on Phathom Pharmaceuticals, each setting a price target of $28.00. Both firms emphasize the significance of securing this extended exclusivity, which would protect the company’s market position and potentially increase its valuation. Stifel notes that the shares are trading below their fundamental value, reflecting the uncertainty surrounding the exclusivity issue. The company remains optimistic about receiving a favorable response from the FDA within the 180-day informal deadline set by the petition. Meanwhile, H.C. Wainwright highlights that the exclusivity could broadly apply to all VOQUEZNA tablet products, although further clarity is needed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.